Advanced Cell Technology Inc. of Marlborough said it has received clearance for a U.K. clinical trial involving human embryonic stem cells.
ACT said the U.K. Medicines and Healthcare products Regulatory Agency agreed to a Phase ½ clinical trial for Stargardt’s Macular Dystrophy using a therapy derived from the stem cells. Stargardt’s disease causes sight loss and can’t be treated yet.
The company has already begun clinical trials for the treatment in the U.S.
